Letters to the Editor

Dual intracellular targeting by ruxolitinib and the Mcl-1 inhibitor S63845 in interleukin-6-dependent myeloma cells blocks

Division of Stem Cell Transplantation and Immunotherapy, Department of Medicine II, University Medical Center Schleswig-Holstein and University of Kiel, Kiel
Division of Stem Cell Transplantation and Immunotherapy, Department of Medicine II, University Medical Center Schleswig-Holstein and University of Kiel, Kiel
Division of Stem Cell Transplantation and Immunotherapy, Department of Medicine II, University Medical Center Schleswig-Holstein and University of Kiel, Kiel
Division of Stem Cell Transplantation and Immunotherapy, Department of Medicine II, University Medical Center Schleswig-Holstein and University of Kiel, Kiel
Division of Stem Cell Transplantation and Immunotherapy, Department of Medicine II, University Medical Center Schleswig-Holstein and University of Kiel, Kiel
Vol. 106 No. 9 (2021): September, 2021 https://doi.org/10.3324/haematol.2020.276865